In a new study, Neurocern AI identifies patients who have a high probability of cognitive impairment earlier and more accurately than a typical doctor, translating to more than $20M in uncaptured HCC revenue per 100,000 patients.
(CHICAGO, IL) — Neurocern announced today a savings outcome of $370M over five years by leveraging artificial intelligence (AI) and neuroinformatics to guide patients to the right Alzheimer’s treatment at the right time. As new disease modifying treatments for Alzheimer’s disease continue to emerge, Medicare and private health insurance plans need data-driven methods to screen, identify, and guide patients to…
Listen now: Neurocern CEO and Founder Dr. Anitha Rao and Milliman actuary, Robert Eaton, are featured on the Society of Actuaries Research Insights Podcast.
The Neurocern team recently partnered with Milliman and the Society of Actuaries to use our proprietary Alzheimer’s Disease and Related Disorders Neurology Desert Index (ANDI) scores to explore the relationship between geographic distribution of neurology specialists and the incidence of long-term care insurance (LTCI) cognitive claims.
We’re thrilled to introduce the Neuro Health Blog. Here, our team will share the latest news, leading insights, and globally recognized research at the forefront of neurology, predictive analytics, big data, and more.